Why CytomX Therapeutics, Inc.’s (CTMX) Stock Is Down 5.27%
As of Wednesday, September 23, CytomX Therapeutics, Inc.’s CTMX share price has dipped by 5.27%, which has investors questioning if this is right time to buy.Jenna Brashear
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company that focuses on developing potent biologics designed to treat tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company’s development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna; and clinical trial collaboration and supply agreement with Merck for the evaluation of CX-801 in combination with anti-PD-1 therapy, KEYTRUDA (pembrolizumab). The company was founded in 2008 and is based in South San Francisco, California.
Commentary & Analysis
Why CytomX Therapeutics, Inc.’s (CTMX) Stock Is Up 6.13%
As of Wednesday, September 16, CytomX Therapeutics, Inc.’s CTMX share price has surged by 6.13%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Why CytomX Therapeutics, Inc.’s (CTMX) Stock Is Down 8.75%
As of Tuesday, September 15, CytomX Therapeutics, Inc.’s CTMX share price has dipped by 8.75%, which has investors questioning if this is right time to buy.Michael Rose
Why CytomX Therapeutics, Inc.’s (CTMX) Stock Is Down 11.72%
As of Tuesday, September 15, CytomX Therapeutics, Inc.’s CTMX share price has dipped by 11.72%, which has investors questioning if this is right time to buy.Omar Beirat
Why CytomX Therapeutics, Inc.’s (CTMX) Stock Is Up 6.99%
As of Tuesday, September 01, CytomX Therapeutics, Inc.’s CTMX share price has surged by 6.99%, which has investors questioning if this is right time to sell.Michael Rose
Financial Summary
| Share Statistics | CTMX | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $588.3 | $257.9 | 39% |
|
| Shares Out (Mil) | 218.9 | 54.3 | 78% |
|
| Institutional Ownership | 99.4% | 92.9% | 88% |
|
| Float (Mil) | 179.8 | 41.4 | 72% |
|
| Beta | 2.14 | 0.95 | 93% |
|
| Avg Daily Volume (000s) | 5,565 | 674 | 92% |
|
| Price Change (52-week) |
12.0% | 51.5% | 62% |
|
| Growth | CTMX | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 2.2% | 13.2% | 24% |
|
| Net Income (5yr) | 23.1% | (10.1%) | 77% |
|
| EPS (5yr) | 36.1% | 15.8% | 86 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (35.5%) | (15.6%) | 15% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 7 | 7 | 7 | |
| Current EPS | ($0.071) | ($0.390) | ($0.473) | |
| Month Ago EPS | ($0.071) | ($0.390) | ($0.473) | |
| # Rev Up | 1 | 1 | 1 | |
| # Rev Down | 0 | 0 | 0 | |
| Three Months Ago EPS | ($0.105) | ($0.421) | ($0.486) | |
| Year/Year Chg | (24.5%) | 160.0% | 251.3% | |
| Financials | CTMX | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $18 | $37 | 12% |
|
| Net Income (TTM) (Mil) | ($80) | ($43) | 13% |
|
| EPS (TTM) | ($0.452) | ($1.600) | 28% |
|
| Operating Cash Flow (TTM) (Mil) | ($82) | ($32) | 7% |
|
| Net Cash Flow (TTM) (Mil) | ($31) | $2 | 23% |
|
| Long-Term Debt (Q1) (Mil) | $4 | $4 | 23% |
|
| Enterprise Value (Q1) (Mil) | $277 | $174 | 29% |
|
| Valuation | CTMX | Industry Median |
Percentile (All Stocks) |
|
| P/B | 1.94 | 2.51 | 51% |
|
| P/E | na | 19.4 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | CTMX | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 100.0% | 68.9% | 96% |
|
| Net Margin | (435.2%) | (72.5%) | 2% |
|
| ROA | (28.6%) | (47.7%) | 17% |
|
| ROE | (37.8%) | (54.9%) | 18% |
|
| Liabilities to Assets | 20.8% | 29.1% | 14% |
|
| F-Score | 1 | 3 | 1% |
|
CytomX Therapeutics, Inc. did not pass any screens on 9/25/2026.
